Mansfield, A. S. http://orcid.org/0000-0002-9483-6903
Wei, Z. http://orcid.org/0000-0001-9234-3497
Mehra, R.
Shaw, A. T.
Lieu, C. H. http://orcid.org/0000-0002-4852-4642
Forde, P. M. http://orcid.org/0000-0001-6925-6344
Drilon, A. E. http://orcid.org/0000-0001-6806-9061
Mitchell, E. P.
Wright, J. J.
Takebe, N.
Sharon, E.
Hovelson, D. http://orcid.org/0000-0003-1881-4451
Tomlins, S.
Zeng, J.
Poorman, K.
Malik, N.
Gray, R. J. http://orcid.org/0000-0002-5724-4917
Li, S.
McShane, L. M.
Rubinstein, L. V. http://orcid.org/0000-0002-9720-9737
Patton, D. http://orcid.org/0000-0003-3855-0166
Williams, P. M. http://orcid.org/0000-0002-3309-5988
Hamilton, S. R.
Conley, B. A.
Arteaga, C. L.
Harris, L. N.
O’Dwyer, P. J.
Chen, A. P.
Flaherty, K. T.
Article History
Received: 24 June 2021
Accepted: 16 December 2021
First Online: 1 March 2022
Competing interests
: Mansfield: Direct research funding: Novartis, and Verily; Honoraria to institution for participation in advisory boards: AbbVie, BeiGene, BMS, Genentech, Inc., Janssen; Travel support: Roche, and non-remunerated member of the Mesothelioma Applied Research Foundation Board of Directors. Forde: Consultant/Advisory boards: Abbvie, AstraZeneca, BMS, Janssen. Research Funding (to institution): AstraZeneca, BMS. Dr. Shaw has served as a compensated consultant or received honoraria from Achilles, Archer, Ariad/Takeda, Bayer, Blueprint Medicines, Chugai, Daiichi-Sankyo, EMD Serono, Foundation Medicine, Guardant, Ignyta, KSQ Therapeutics, Loxo Oncology, Natera, Novartis, Pfizer, Roche-Genentech, Servier, Syros, Taiho Pharmaceutical, and TP Therapeutics; received institutional research funding from Ariad, Ignyta, Novartis, Pfizer, Roche-Genentech, and TP Therapeutics; received travel support from Genentech and Pfizer, and is currently employed by and owns stock in Novartis. Drilon: Honoraria/Advisory Boards: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, Remedica Ltd., ArcherDX, Monopteros, Novartis, EMD Serono, Melendi; Research to Institution: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar; Royalties: Wolters Kluwer; OTHER: Merck, Puma, Merus, Boehringer Ingelheim. Hovelson: Equity holder and employee of Strata Oncology. Tomlins: Equity holder and employee of Strata Oncology. Named as co-inventors on a patent issued to Strata Oncology related to MSI status assessment. Named as co-inventor and included in royalty streams for a patent issued to the University of Michigan regarding ETS fusions in prostate cancer that has been licensed to Hologic/Gen-Probe (sublicensed to Ventana Medical Systems) and LynxDx. Equity holder in Javelin Oncology. Previously served as a consultant to Strata Oncology and has consulted for Astellas/Medivation and Janssen. He has received research (to the University of Michigan) funding from Astellas and has received travel support from the Prostate Cancer Foundation. Hamilton: Consultant/Advisory Boards: Merck, Incyte, Bristol Myers Squibb, GSK, Loxo, Roche, Thermo Fisher Scientific, illmina, HalioDx. Research Funding to Institution: Guardant Health, CME: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences. Arteaga: reported receiving grants from Lilly, Pfizer, and Takeda; serving in an expert advisory role to Novartis, Lilly, Immunomedics, Merck, Daiichi Sankyo, Taiho Oncology, AstraZeneca, and OrigiMed outside the submitted work; holding minor stock options in Y-TRAP and Provista, and serving in the Scientific Advisory Board of the Susan G. Komen Foundation. All remaining authors have declared no conflicts of interest.